Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
09 Sep 2024
Historique:
received: 25 03 2024
accepted: 30 08 2024
medline: 10 9 2024
pubmed: 10 9 2024
entrez: 9 9 2024
Statut: epublish

Résumé

Bortezomib, lenalidomide, and dexamethasone (VRD), and bortezomib, doxorubicin, and dexamethasone (PAD), are commonly used in induction regimens for patients with newly diagnosed multiple myeloma (NDMM) in China. This real-world study enrolled 390 patients, 195 receiving VRD and 195 receiving PAD induction. The primary endpoint was progression-free survival (PFS) and stringent complete remission/complete remission. Across the entire cohort, VRD demonstrated significantly improved five-year overall survival (OS) (74% vs. 59%, p = 0.0024) and five-year PFS (67% vs. 37%, p = 0.0018) compared to PAD. Notably, the median OS and PFS were not reached for VRD-treated patients, while they were 77 months (60-not reached [NR]) and 46 months (36-NR), respectively, for PAD. In patients with standard-risk cytogenetics, VRD showed superior five-year OS (83% vs. 58%, p = 0.0038) and PFS (78% vs. 48%, p = 0.0091) compared to PAD. However, these differences were not statistically significant in high-risk patients. For transplanted patients, VRD was associated with superior five-year OS (91% vs. 67%, p = 0.014) and PFS (79% vs. 47%, p = 0.015) compared to PAD. In non-transplanted patients, VRD showed a trend towards improved five-year OS (p = 0.085) and PFS (p = 0.073) compared to the PAD group. In conclusion, VRD displayed superior OS and PFS outcomes in standard-risk patients and those who underwent transplantation. These findings suggest potential advantages of VRD over PAD in real-world clinical settings for NDMM treatment. However, due to the imbalance in transplantation rates between the VRD and PAD groups, limitations in testing for high-risk cytogenetic abnormalities (HRA), and the difference between the received cycles and salvage therapies, the conclusions of this study should be interpreted with caution.

Identifiants

pubmed: 39251979
doi: 10.1186/s12885-024-12880-9
pii: 10.1186/s12885-024-12880-9
doi:

Substances chimiques

Bortezomib 69G8BD63PP
Dexamethasone 7S5I7G3JQL
Lenalidomide F0P408N6V4
Doxorubicin 80168379AG

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1123

Subventions

Organisme : Yang Liang
ID : 201603
Organisme : Hua Wang
ID : 81700148

Informations de copyright

© 2024. The Author(s).

Références

Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77. https://doi.org/10.1001/jama.2022.0003 .
doi: 10.1001/jama.2022.0003 pubmed: 35103762
Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928–37. https://doi.org/10.1200/JCO.19.02515 .
doi: 10.1200/JCO.19.02515 pubmed: 32298201 pmcid: 7587409
Bergsagel DE. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol. 1989;25(2):159–61. https://doi.org/10.1016/0277-5379(89)90001-1 .
doi: 10.1016/0277-5379(89)90001-1 pubmed: 2649372
Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. J Am Soc Hematol Blood. 2010;116(5):679–86. https://doi.org/10.1182/blood-2010-02-268862 .
doi: 10.1182/blood-2010-02-268862
Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. J Am Soc Hematol Blood. 2019;134(16):1337–45. https://doi.org/10.1182/blood.2019000241 .
doi: 10.1182/blood.2019000241
Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53. https://doi.org/10.1038/s41408-020-0311-8 .
doi: 10.1038/s41408-020-0311-8 pubmed: 32393732 pmcid: 7214419
Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27. https://doi.org/10.1016/S0140-6736(16)31594-X .
doi: 10.1016/S0140-6736(16)31594-X pubmed: 28017406
Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946–55. https://doi.org/10.1200/JCO.2011.39.6820 .
doi: 10.1200/JCO.2011.39.6820 pubmed: 22802322
Mai EK, Bertsch U, Dürig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721–9. https://doi.org/10.1038/leu.2015.80 .
doi: 10.1038/leu.2015.80 pubmed: 25787915
Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) frontline treatment of multiple myeloma: updated results after long-term follow‐up. Br J Haematol. 2008;141(4):512–6. https://doi.org/10.1111/j.1365-2141.2008.06997.x .
doi: 10.1111/j.1365-2141.2008.06997.x pubmed: 18371113
Huang BT, Tan Y, Zhao WH, et al. How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. J Cancer Res Clin Oncol. 2014;140(2):303–9. https://doi.org/10.1007/s00432-013-1570-6 .
doi: 10.1007/s00432-013-1570-6 pubmed: 24337419
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6 .
doi: 10.1016/S1470-2045(16)30206-6 pubmed: 27511158
Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18–30. https://doi.org/10.1038/s41375-020-01012-4 .
doi: 10.1038/s41375-020-01012-4 pubmed: 32778736
Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600. https://doi.org/10.1200/JCO.2013.48.7934 .
doi: 10.1200/JCO.2013.48.7934 pubmed: 24419113 pmcid: 3918540
Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020;21(12):e540. https://doi.org/10.1016/S1470-2045(20)30635-5 .
doi: 10.1016/S1470-2045(20)30635-5 pubmed: 33271097
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–20. https://doi.org/10.1056/NEJMoa1611750 .
doi: 10.1056/NEJMoa1611750 pubmed: 28379796 pmcid: 6201242
Sidiqi MH, Aljama MA, Bin Riaz I, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer J. 2018;8(11):106. https://doi.org/10.1038/s41408-018-0147-7 .
doi: 10.1038/s41408-018-0147-7 pubmed: 30409963 pmcid: 6224498
Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. Cancers. 2021;13(4):863. https://doi.org/10.3390/cancers13040863 .
doi: 10.3390/cancers13040863 pubmed: 33670709 pmcid: 7922596
Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929. https://doi.org/10.1016/j.ctrv.2019.101929 .
doi: 10.1016/j.ctrv.2019.101929 pubmed: 31770695
Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. J Am Soc Hematol Blood. 2011;118(3):529–34. https://doi.org/10.1182/blood-2011-01-332320 .
doi: 10.1182/blood-2011-01-332320
O’Gorman P, Laubach JP, O’Dwyer ME, et al. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. Am J Hematol. 2022;97(5):562–73. https://doi.org/10.1002/ajh.26491 .
doi: 10.1002/ajh.26491 pubmed: 35132679
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med. 2024;390(4):301–13. https://doi.org/10.1056/NEJMoa2312054 .
doi: 10.1056/NEJMoa2312054 pubmed: 38084760
Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood J Am Soc Hematol. 2020;136(8):936–45. https://doi.org/10.1182/blood.2020005288 .
doi: 10.1182/blood.2020005288
Facon T, Cook G, Usmani SZ, et al. Daratumumab plus Lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA[J]. Leukemia. 2022;36(4):1066–77. https://doi.org/10.1038/s41375-021-01488-8 .
doi: 10.1038/s41375-021-01488-8 pubmed: 34974527 pmcid: 8979809
Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. NEW ENGL J MED. 2024. https://doi.org/10.1056/NEJMoa2400712 .
doi: 10.1056/NEJMoa2400712 pubmed: 38832972

Auteurs

Dong Liang (D)

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Shenrui Bai (S)

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Demei Feng (D)

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Guanjun Chen (G)

Department of Oncology, Third Xiangya Hospital of Central South University, Changsha, China.

Yang Liang (Y)

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China. liangyang@sysucc.org.cn.

Hua Wang (H)

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China. wanghua@sysucc.org.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH